Frederiksberg, Denmark

Tommy Liljefors



 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2013-2014

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Tommy Liljefors: Innovator in GABA Receptor Modulation

Introduction

Tommy Liljefors is a notable inventor based in Frederiksberg, Denmark. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that modulate GABA receptors. With a total of 2 patents, his work focuses on addressing various conditions related to anxiety and convulsions.

Latest Patents

Liljefors' latest patents include novel compounds that serve as GABA receptor modulators. The first patent relates to compounds with anxiolytic, anticonvulsant, sedative-hypnotic, and myorelaxant properties. These compounds are designed to treat conditions such as anxiety and convulsions in mammals, including humans. The second patent involves GABA/BzR ligands that can be utilized for similar therapeutic purposes, showcasing his innovative approach to addressing mental health and neurological conditions.

Career Highlights

Throughout his career, Tommy Liljefors has worked with various companies, including Innovationspatent Sverige AB and Gabather AB. His experience in these organizations has allowed him to refine his expertise in drug development and patenting innovative solutions for complex health issues.

Collaborations

Some of his notable coworkers include Mogens Peter Cherly Nielsen and Jakob Nilsson. Their collaborative efforts have contributed to the advancement of research in the field of GABA receptor modulation.

Conclusion

Tommy Liljefors stands out as an influential inventor in the realm of pharmacology, with a focus on GABA receptor modulation. His patents reflect a commitment to developing effective treatments for anxiety and convulsions, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…